Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Translational Neuroscience, Osaka City University Graduate School of Medicine, had previously shown in a study using mice that the antibiotic rifampicin removes oligomers from the brain and improves cognitive function. However, the drug has been associated with side effects such as liver damage. Resveratrol, a naturally occurring antioxidant in plants, is used as a supplement in Europe and the United States. “To combat the negative side effects of the existing drug rifampicin, we thought of combining it with the hepatoprotective effects of resveratrol,” illustrates Professor Takami Tomiyama, who acted as lead investigator for the current study.
This time, the research group administered a fixed dose combination of rifampicin and resveratrol intranasally five days a week for a total of four weeks to mice models of Alzheimer’s disease, frontotemporal dementia, and dementia with Lewy bodies, and observed their cognitive functions and brain pathology. The results showed that the combination significantly improved the cognitive function of the mice, inhibited the accumulation of oligomers, and restored synaptophysin levels – presynaptic proteins that facilitate synapses. Additionally, blood levels of liver enzymes, a marker of hepatic damage that normally increases with rifampicin, remained normal in the fixed-dose combination. Furthermore, increased levels of brain-derived neurotrophic factor (BDNF) expression were observed in the hippocampus, which was not seen with rifampicin alone. These results indicate that this fixed-dose combination is superior to rifampicin alone in terms of both safety and efficacy.
The results of this study were published online in the Swiss scientific journal Frontiers in Neuroscience on December 13, 2021.
“The number of patients with dementia has been increasing all over the world, with some sources predicting a doubling of patients every 20 years. However, there is still no effective treatment for the disease,” states Specially Appointed Lecturer Tomohiro Umeda, first author of the study. “Recent studies have shown that abnormalities begin to appear in the brains of dementia patients more than 20 years before the onset of the disease.” By investigating new therapeutic purposes with existing drugs in a process called drug repositioning, the research team hopes to diagnose and prevent dementia before the neurons start dying.
Furthermore, based on the team’s previous research experience, nasal administration of a fixed dose combination of rifampicin and resveratrol would increase drug transferability to the brain and further enhance both safety and medicinal effects. The dosage used in this study was 0.02 mg of rifampicin per mouse per day, or 1 mg/kg/day assuming a mouse weight of 20g. “Converted to a human dosage based on body surface area, it becomes 0.081 mg/kg/day,” states Prof. Tomiyama, “currently, rifampicin is prescribed at 10 mg/kg/day as an antibiotic, and compared to this, we confirmed an effect at a much lower dosage.”
The development of a fixed-dose combination of rifampicin and resveratrol nasal spray is currently being carried out by Medilabo RFP, a venture company originating from the research team’s laboratory. Following the publication of this paper, Medilabo RFP has begun preparations for global clinical trials. In November 2021, with the support of the Japan External Trade Organization (JETRO), Medilabo RFP has established a subsidiary in Massachusetts, USA.
The technology developed in this study for rifampicin + resveratrol fixed-dose nasal spray has been patented (PCT/JP2018/025512, PCT/JP2019/000278)
We are Osaka City University – the oldest research university in Osaka. With 9 undergraduate faculties and 11 graduate schools all dedicated to making urban life better, energy cleaner, and people healthier and happier, we have won numerous awards and have produced 2 Nobel laureates. For more information, please visit our website at https://www.upc-osaka.ac.jp/new-univ/en-research/
Frontiers in Neuroscience
METHOD OF RESEARCH
SUBJECT OF RESEARCH
Oligomer-targeting prevention of neurodegenerative dementia by intranasal rifampicin and resveratrol combination – a preclinical study in model mice
ARTICLE PUBLICATION DATE
Tomohiro Umeda, Toru Kumagai, and Takami Tomiyama have applied for a patent on intranasal rifampicin and resveratrol combination for neurodegenerative dementia (PCT/JP2019/000278). Toru Kumagai and Takami Tomiyama are the founders of Medilabo RFP, Inc., who is developing nasal rifampicin. This study received funding from Medilabo RFP, Inc., The funder had the following involvement with the study: Toru Kumagai proposed the drug combination study, and Takami Tomiyama designed the study, conducted the drug administration, immunohistochemical staining, western blotting, and wrote the manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Source: Stopping dementia at the nose with combination of rifampicin and resveratrol
You must log in to post a comment.